A specialty clinical AI company
No patient should pay with their kidneys, heart, or eyes for a dose decision that was simply never made. MetaHealth360°C builds AI-first software that helps specialists make the right next decision on the right next day.
Why we exist
Medicine already knows how to control diabetes, hypertension, lipids, and most chronic diseases. What it doesn’t reliably do — anywhere in the world — is make the next titration decision on time. That gap is called clinical inertia, and it is the most preventable cause of chronic-disease harm.
~70%
of insulin-treated type-2 patients in India never reach HbA1c target.
<15%
of India’s 188M hypertensives have their blood pressure controlled.
Years
of avoidable kidney, heart and eye damage accrue between visits.
We’re building the decision layer that closes that gap. One condition at a time, with clinicians in the loop, anchored to the evidence they already trust.
Crushing inertia. / Empowering action. / Reversing diseases.
The MetaHealth360°C motto
The Titria family
Every Titria product runs on the same clinical AI brain — Titria Health — and is tuned for one chronic condition. We focus on basal insulin first. Hypertension is next. The platform expands one disease at a time, never faster than the evidence.
Active build
AI titration for basal insulin
A clinician-facing software-as-a-medical-device that recommends the next basal insulin dose between visits — guideline-anchored, audit-trailed, and built for Indian specialists who manage type-2 diabetes every day.
In development · MVP 2026
Platform
The clinical AI brain
The shared reasoning, guideline-ingestion and clinician-chat layer behind every Titria product. Specialty-grade, evaluation-first, hardware-agnostic. Also available as a standalone clinical companion app.
Powers Titria · Standalone coming
Next
AI titration for blood pressure
The same titration brain, tuned for antihypertensive therapy in Indian patients. Anchored to ESC/ESH 2024 and ICMR/IHCI guidance, with single-pill-combination logic for diabetologists who manage hypertension every day.
Coming after Titria
Future products under the Titria family — PCOS, thyroid, lipids, CKD — will be announced only when they enter active development. We do not promise what we have not started.
How we build
Every recommendation is generated by AI and approved by the clinician. No autonomous prescribing. The doctor is always in the loop.
Every dose suggestion is traceable to a citable source — ESC/ESH, ADA, ICMR, RSSDI, WHO HEARTS. Evidence is the substrate, not the marketing.
Built for Indian specialists, Indian thresholds, Indian comorbidities, Indian regulator. We start where the inertia is largest and the tooling thinnest.
We ingest readings from any validated cuff, CGM or lab. We will never ask a doctor or patient to buy hardware to use our software.
A lean, AI-native operating model. No human ops layer between the algorithm and the clinician. The company stays small so the software stays sharp.
Founder
Founder & CTO, MetaHealth360°C
Metabolic physician practising in Mumbai, India. Fifteen years managing type-2 diabetes, insulin therapy, PCOS and metabolic syndrome in Indian patients. The Why behind MetaHealth360°C was earned in clinic — watching the same preventable harms recur because the next dose decision was simply never made.
Stay close
One email when Titria opens to clinicians. One when Titria Hypertension begins clinical evaluation. Nothing else. No newsletter, no funnel.
Investor or partnership enquiries: hello@metahealth360.in